Sanofi, Denali Neuro Drug Fails Mid-Stage Trial in ALS; MS Study Is ...
An ALS drug candidate, DNL788/SAR443820, by Sanofi and Denali Therapeutics failed a Phase 2 trial, missing the main endpoint on the ALS Functional Rating Scale-Revised. Despite strong Phase 1 results, the failure questions RIPK1 inhibition's efficacy for ALS treatment. Further insights may come from an ongoing 52-week extension study. Meanwhile, other RIPK1 inhibitors and ALS treatments continue development.
Reference News
An ALS drug candidate, DNL788/SAR443820, by Sanofi and Denali Therapeutics failed a Phase 2 trial, missing the main endpoint on the ALS Functional Rating Scale-Revised. Despite strong Phase 1 results, the failure questions RIPK1 inhibition's efficacy for ALS treatment. Further insights may come from an ongoing 52-week extension study. Meanwhile, other RIPK1 inhibitors and ALS treatments continue development.